Document Detail


Cellular targeting in autoimmunity.
MedLine Citation:
PMID:  23054625     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Many biologic agents that were first approved for the treatment of malignancies are now being actively investigated and used in a variety of autoimmune diseases such as rheumatoid arthritis (RA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, systemic lupus erythematosus (SLE), and Sjogren's syndrome. The relatively recent advance of selective immune targeting has significantly changed the management of autoimmune disorders and in part can be attributed to the progress made in understanding effector cell function and their signaling pathways. In this review, we will discuss the recent FDA-approved biologic therapies that directly target immune cells as well as the most promising investigational drugs affecting immune cell function and signaling for the treatment of autoimmune disease.
Authors:
Jennifer L Rogers; Donald S Serafin; Roman G Timoshchenko; Teresa K Tarrant
Related Documents :
23859695 - Current opinion on 3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-...
24247915 - Proteasomes and proteasomal gene polymorphism in association with inflammation and vari...
24819215 - "in vitro" 3d models of tumor-immune system interaction.
24735815 - Geniposide suppresses lps-induced nitric oxide, pge2 and inflammatory cytokine by downr...
17485405 - Cytokine quantitation: technologies and applications.
21168185 - Coagulation and autoimmunity in scleroderma interstitial lung disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current allergy and asthma reports     Volume:  12     ISSN:  1534-6315     ISO Abbreviation:  Curr Allergy Asthma Rep     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-08     Completed Date:  2013-04-10     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  101096440     Medline TA:  Curr Allergy Asthma Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  495-510     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy,  immunology
Autoimmune Diseases / drug therapy*,  immunology*
Autoimmunity / drug effects*,  immunology
B-Lymphocytes / drug effects,  immunology
Biological Therapy
Humans
Immunity, Cellular / drug effects*
Immunosuppressive Agents / therapeutic use
Lupus Erythematosus, Systemic / drug therapy,  immunology
Protein-Tyrosine Kinases / drug effects,  immunology
Sjogren's Syndrome / drug therapy,  immunology
T-Lymphocytes / drug effects,  immunology
Grant Support
ID/Acronym/Agency:
R03 AR059286/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Murine-Derived; 0/Antineoplastic Agents; 0/Immunosuppressive Agents; 0/rituximab; EC 2.7.10.1/Protein-Tyrosine Kinases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cytokine Responses in the Common Cold and Otitis Media.
Next Document:  Progress in Understanding the Epigenetic Basis for Immune Development, Immune Function, and the Risi...